FY2025 EPS Estimates for Amgen Boosted by Cantor Fitzgerald

Amgen Inc. (NASDAQ:AMGN) – Stock analysts at Cantor Fitzgerald increased their FY2025 earnings per share estimates for shares of Amgen in a report released on Friday, May 2nd. Cantor Fitzgerald analyst C. Gould now anticipates that the medical research company will earn $20.85 per share for the year, up from their previous forecast of $20.50. Cantor Fitzgerald has a “Neutral” rating and a $305.00 price objective on the stock. The consensus estimate for Amgen’s current full-year earnings is $20.62 per share.

Several other brokerages also recently commented on AMGN. Wells Fargo & Company reiterated an “equal weight” rating on shares of Amgen in a report on Wednesday, February 5th. Royal Bank of Canada dropped their price objective on shares of Amgen from $324.00 to $320.00 and set an “outperform” rating for the company in a report on Friday, May 2nd. Piper Sandler raised their price target on Amgen from $310.00 to $329.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Citigroup restated a “neutral” rating on shares of Amgen in a report on Wednesday, February 5th. Finally, Truist Financial lowered their price objective on shares of Amgen from $333.00 to $298.00 and set a “hold” rating for the company in a research report on Wednesday, January 8th. Two analysts have rated the stock with a sell rating, ten have given a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $308.18.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $270.56 on Monday. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The stock has a market capitalization of $145.47 billion, a P/E ratio of 35.84, a P/E/G ratio of 2.63 and a beta of 0.51. The business has a 50-day moving average of $298.42 and a two-hundred day moving average of $290.64. Amgen has a fifty-two week low of $253.30 and a fifty-two week high of $346.85.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, topping the consensus estimate of $4.18 by $0.72. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The company had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. During the same period in the previous year, the firm posted $3.96 earnings per share. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be given a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.52%. Amgen’s dividend payout ratio is 126.09%.

Insider Activity

In other Amgen news, EVP Jonathan P. Graham sold 25,045 shares of the business’s stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $293.12, for a total value of $7,341,190.40. Following the completion of the transaction, the executive vice president now directly owns 28,987 shares of the company’s stock, valued at approximately $8,496,669.44. The trade was a 46.35 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP David M. Reese sold 8,711 shares of the firm’s stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $293.22, for a total value of $2,554,239.42. Following the sale, the executive vice president now directly owns 62,147 shares in the company, valued at approximately $18,222,743.34. This represents a 12.29 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 67,752 shares of company stock valued at $20,160,532 in the last quarter. Company insiders own 0.69% of the company’s stock.

Institutional Investors Weigh In On Amgen

Several large investors have recently made changes to their positions in AMGN. Wilkins Investment Counsel Inc. bought a new position in Amgen during the 1st quarter worth about $234,000. Neo Ivy Capital Management boosted its position in shares of Amgen by 590.4% during the first quarter. Neo Ivy Capital Management now owns 9,548 shares of the medical research company’s stock worth $2,975,000 after buying an additional 8,165 shares during the period. ANB Bank grew its holdings in shares of Amgen by 1.3% during the first quarter. ANB Bank now owns 3,868 shares of the medical research company’s stock worth $1,205,000 after buying an additional 51 shares in the last quarter. Cetera Investment Advisers raised its position in Amgen by 13.2% in the 1st quarter. Cetera Investment Advisers now owns 226,219 shares of the medical research company’s stock valued at $70,479,000 after buying an additional 26,309 shares during the last quarter. Finally, Avantax Advisory Services Inc. lifted its stake in Amgen by 7.2% in the 1st quarter. Avantax Advisory Services Inc. now owns 93,240 shares of the medical research company’s stock valued at $29,049,000 after acquiring an additional 6,266 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.